<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="acn352295" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Clin Transl Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Clin Transl Neurol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2328-9503</journal-id><journal-id journal-id-type="publisher-id">ACN3</journal-id><journal-title-group><journal-title>Annals of Clinical and Translational Neurology</journal-title></journal-title-group><issn pub-type="epub">2328-9503</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40051075</article-id><article-id pub-id-type="pmc">PMC12093344</article-id>
<article-id pub-id-type="doi">10.1002/acn3.52295</article-id><article-id pub-id-type="publisher-id">ACN352295</article-id><article-id pub-id-type="other">ACN3-2024-06-0656.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Relationship of cognitive decline with glucocerebrosidase activity and amyloid&#x02010;beta 42 in <styled-content style="fixed-case" toggle="no">DLB</styled-content> and <styled-content style="fixed-case" toggle="no">PD</styled-content>
</article-title><alt-title alt-title-type="right-running-head">Biomarkers of GCase &#x00026; AB42 in DLB and PD</alt-title><alt-title alt-title-type="left-running-head">M. C. Gonzalez <italic toggle="no">et&#x000a0;al.</italic>
</alt-title></title-group><contrib-group><contrib id="acn352295-cr-0001" contrib-type="author" corresp="yes"><name><surname>Gonzalez</surname><given-names>Maria Camila</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1061-4164</contrib-id><xref rid="acn352295-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352295-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acn352295-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>maria.c.gonzalezvelez@uis.no</email></address></contrib><contrib id="acn352295-cr-0002" contrib-type="author"><name><surname>Oftedal</surname><given-names>Linn</given-names></name><xref rid="acn352295-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acn352295-cr-0003" contrib-type="author"><name><surname>Lange</surname><given-names>Johannes</given-names></name><xref rid="acn352295-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acn352295-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acn352295-cr-0004" contrib-type="author"><name><surname>Tovar&#x02010;Rios</surname><given-names>Diego Alejandro</given-names></name><xref rid="acn352295-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352295-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acn352295-cr-0005" contrib-type="author"><name><surname>Tysnes</surname><given-names>Ole&#x02010;Bj&#x000f8;rn</given-names></name><xref rid="acn352295-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="acn352295-cr-0006" contrib-type="author"><name><surname>Paquet</surname><given-names>Claire</given-names></name><xref rid="acn352295-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="acn352295-cr-0007" contrib-type="author"><name><surname>Marqui&#x000e9;</surname><given-names>Marta</given-names></name><xref rid="acn352295-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="acn352295-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="acn352295-cr-0008" contrib-type="author"><name><surname>Boada</surname><given-names>Merc&#x000e8;</given-names></name><xref rid="acn352295-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="acn352295-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="acn352295-cr-0009" contrib-type="author"><name><surname>Alcolea</surname><given-names>Daniel</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3819-3245</contrib-id><xref rid="acn352295-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="acn352295-cr-0010" contrib-type="author"><name><surname>Rejdak</surname><given-names>Konrad</given-names></name><xref rid="acn352295-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="acn352295-cr-0011" contrib-type="author"><name><surname>Papuc</surname><given-names>Ewa</given-names></name><xref rid="acn352295-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="acn352295-cr-0012" contrib-type="author"><name><surname>Hort</surname><given-names>Jakub</given-names></name><xref rid="acn352295-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="acn352295-cr-0013" contrib-type="author"><name><surname>Falup&#x02010;Pecurariu</surname><given-names>Cristian</given-names></name><xref rid="acn352295-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="acn352295-cr-0014" contrib-type="author"><name><surname>Aarsland</surname><given-names>Dag</given-names></name><xref rid="acn352295-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="acn352295-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="acn352295-cr-0015" contrib-type="author"><name><surname>Alves</surname><given-names>Guido</given-names></name><xref rid="acn352295-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acn352295-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="acn352295-cr-0016" contrib-type="author"><name><surname>Maple&#x02010;Gr&#x000f8;dem</surname><given-names>Jodi</given-names></name><xref rid="acn352295-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acn352295-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="acn352295-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Quality and Health Technology, Faculty of Health Sciences</named-content>
<institution>University of Stavanger</institution>
<city>Stavanger</city>
<country country="NO">Norway</country>
</aff><aff id="acn352295-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Centre for Movement Disorders</named-content>
<institution>Stavanger University Hospital</institution>
<city>Stavanger</city>
<country country="NO">Norway</country>
</aff><aff id="acn352295-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Centre for Age&#x02010;Related Medicine</named-content>
<institution>Stavanger University Hospital</institution>
<city>Stavanger</city>
<country country="NO">Norway</country>
</aff><aff id="acn352295-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Chemistry, Bioscience and Environmental Engineering</named-content>
<institution>University of Stavanger</institution>
<city>Stavanger</city>
<country country="NO">Norway</country>
</aff><aff id="acn352295-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Haukeland University Hospital</institution>
<city>Bergen</city>
<country country="NO">Norway</country>
</aff><aff id="acn352295-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Neurology Center, Assistance Publique H&#x000f4;pitaux de Paris, Lariboisi&#x000e8;re Fernand&#x02010;Widal Hospital, INSERMU1144</named-content>
<institution>Universit&#x000e9; de Paris</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="acn352295-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Ace Alzheimer Center Barcelona&#x02013;Universitat Internacional de Catalunya</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="acn352295-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">CIBERNED, Center for Networked Biomedical Research On Neurodegenerative Diseases</named-content>
<institution>National Institute of Health Carlos III</institution>
<city>Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="acn352295-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Sant Pau Memory Unit, Department of Neurology, IIB Sant Pau&#x02014;Hospital de Sant Pau</named-content>
<institution>Universitat Aut&#x000f2;noma de Barcelona</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="acn352295-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Medical University of Lublin</institution>
<city>Lublin</city>
<country country="PL">Poland</country>
</aff><aff id="acn352295-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology, Memory Clinic</named-content>
<institution>Charles University, Second Faculty of Medicine and Motol University Hospital</institution>
<city>Prague</city>
<country country="CZ">Czech Republic</country>
</aff><aff id="acn352295-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology, County Clinic Hospital, Faculty of Medicine</named-content>
<institution>Transilvania University</institution>
<city>Brasov</city>
<country country="RO">Romania</country>
</aff><aff id="acn352295-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Department of Psychological Medicine Institute of Psychiatry</named-content>
<institution>Psychology &#x00026; Neuroscience King's College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="acn352295-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Departement of Neurology</named-content>
<institution>Stavanger University Hospital</institution>
<city>Stavanger</city>
<country country="NO">Norway</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Maria Camila Gonzalez, Stavanger University Hospital, PO Box 8100, Stavanger N&#x02010;4068, Norway. Tel: +47 41244975; Fax: +47 51 51 55 15; E&#x02010;mail: <email>maria.c.gonzalezvelez@uis.no</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>12</volume><issue seq="50">5</issue><issue-id pub-id-type="doi">10.1002/acn3.v12.5</issue-id><fpage>915</fpage><lpage>924</lpage><history>
<date date-type="rev-recd"><day>18</day><month>10</month><year>2024</year></date>
<date date-type="received"><day>27</day><month>6</month><year>2024</year></date>
<date date-type="accepted"><day>16</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 American Neurological Association--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Annals of Clinical and Translational Neurology</italic> published by Wiley Periodicals LLC on behalf of American Neurological Association.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:ACN3-12-915.pdf"/><abstract><title>Abstract</title><sec id="acn352295-sec-0001"><title>Objective</title><p>Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including <italic toggle="no">GBA1</italic> and <italic toggle="no">APOE&#x003b5;4</italic> mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid&#x02010;beta 42 (A&#x003b2;42) levels, may hold potential as predictive indicators, providing valuable insights into the likelihood of cognitive decline within these diagnoses. Our objective was to determine their association with cognitive decline in DLB and PD.</p></sec><sec id="acn352295-sec-0002"><title>Methods</title><p>A total of 121 DLB patients from the European&#x02010;DLB Consortium and 117 PD patients from the Norwegian ParkWest Study were included in this study. The four most commonly associated variants of <italic toggle="no">GBA1</italic> mutations (E326K, T369M, N370S, L444P), <italic toggle="no">APOE&#x003b5;4</italic> status, and cerebrospinal fluid (CSF) A&#x003b2;42 levels and GCase activity were assessed, as well as global cognition using the Mini&#x02010;Mental State Examination. Linear mixed&#x02010;effects regression models were used to evaluate the association of CSF biomarkers with cognitive decline in each diagnostic group, adjusted for age, sex, education, and genetic mutation profile.</p></sec><sec id="acn352295-sec-0003"><title>Results</title><p>Low CSF A&#x003b2;42 levels were associated with accelerated cognitive decline in DLB, whereas reduced CSF GCase activity predicted faster cognitive decline in PD. These associations were independent of <italic toggle="no">GBA1</italic> gene mutations or <italic toggle="no">APOE&#x003b5;4</italic> status.</p></sec><sec id="acn352295-sec-0004"><title>Interpretation</title><p>Our study provides important evidence on the relationship between brain A&#x003b2; deposition and GCase activity in the Lewy body disease spectrum independent of their genetic mutation profile. This information could be relevant for designing future clinical trials targeting these pathways.</p></sec></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Western Norway Regional Health Authority
</institution><institution-id institution-id-type="doi">10.13039/501100004257</institution-id></institution-wrap></funding-source><award-id>911218</award-id><award-id>911949</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Instituto de Salud Carlos III
</institution><institution-id institution-id-type="doi">10.13039/501100004587</institution-id></institution-wrap></funding-source><award-id>PI18/00435</award-id><award-id>PI22/00611</award-id><award-id>INT19/00016</award-id><award-id>INT23/00048</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Research Council of Norway
</institution><institution-id institution-id-type="doi">10.13039/501100005416</institution-id></institution-wrap></funding-source><award-id>177966</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Departament de Salut, Generalitat de Catalunya
</institution><institution-id institution-id-type="doi">10.13039/501100010552</institution-id></institution-wrap></funding-source><award-id>PERIS program SLT006/17/125</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Next Generation EU
</institution><institution-id institution-id-type="doi">10.13039/100031478</institution-id></institution-wrap></funding-source><award-id>LX22NPO5107 MEYS</award-id></award-group><funding-statement>This work was funded by <funding-source><institution-wrap><institution>Western Norway Regional Health Authority
</institution><institution-id institution-id-type="doi">10.13039/501100004257</institution-id></institution-wrap></funding-source> grants <award-id>911218</award-id> and <award-id>911949</award-id>; <funding-source><institution-wrap><institution>Instituto de Salud Carlos III
</institution><institution-id institution-id-type="doi">10.13039/501100004587</institution-id></institution-wrap></funding-source> grants <award-id>PI18/00435</award-id>, <award-id>PI22/00611</award-id>, <award-id>INT19/00016</award-id>, and <award-id>INT23/00048</award-id>; <funding-source><institution-wrap><institution>Research Council of Norway
</institution><institution-id institution-id-type="doi">10.13039/501100005416</institution-id></institution-wrap></funding-source> grant <award-id>177966</award-id>; <funding-source><institution-wrap><institution>Departament de Salut, Generalitat de Catalunya
</institution><institution-id institution-id-type="doi">10.13039/501100010552</institution-id></institution-wrap></funding-source> grant <award-id>PERIS program SLT006/17/125</award-id>; <funding-source><institution-wrap><institution>Next Generation EU
</institution><institution-id institution-id-type="doi">10.13039/100031478</institution-id></institution-wrap></funding-source> grant <award-id>LX22NPO5107 MEYS</award-id>.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="10"/><word-count count="7466"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="acn352295-body-0001"><sec sec-type="background" id="acn352295-sec-0005"><title>Background</title><p>Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) are neurodegenerative disorders classified as neuronal synuclein diseases. They share various clinical, genetic, and pathological features. In both conditions, abnormal alpha&#x02010;synuclein aggregates accumulate in the brain,<xref rid="acn352295-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> which is considered their neuropathological hallmark. Both disorders present a range of symptoms, including motor deficits, neuropsychiatric manifestations, and autonomic dysfunction. Additionally, both disorders exhibit progressive cognitive decline with similar rates of deterioration in the advanced stages of the diseases.<xref rid="acn352295-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> In recent decades, advancements in genetic studies have contributed to breakthroughs in understanding different pathways involved in the development and progression of DLB and PD. Two extensively researched genes associated with DLB and PD are <italic toggle="yes">GBA1</italic> and <italic toggle="yes">APOE</italic>. <italic toggle="yes">GBA</italic> has been identified as a genetic risk factor for the development of DLB and PD. Moreover, besides its role as a genetic risk factor for developing DLB, <italic toggle="yes">APOE</italic> has been shown to influence the presentation and progression of both PD and DLB.<xref rid="acn352295-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="acn352295-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>The <italic toggle="yes">APOE&#x003b5;4</italic> allele has been found to be associated with impaired A&#x003b2; clearance in the brain, leading to the accumulation of amyloid&#x02010;beta (A&#x003b2;) plaques.<xref rid="acn352295-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> While <italic toggle="yes">APOE&#x003b5;4</italic> and A&#x003b2; plaques have been broadly described in both DLB and PD, a major distinction between the two lies in the extent and severity of co&#x02010;existing amyloid pathology. DLB is more frequently associated with the presence of A&#x003b2; plaques than PD.<xref rid="acn352295-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="acn352295-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="acn352295-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> In addition, A&#x003b2; biomarkers are more strongly associated with cognitive impairment in DLB than PD, although results show considerable variation dependent on disease stage, follow&#x02010;up period, and cognitive measures used.<xref rid="acn352295-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="acn352295-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="acn352295-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="acn352295-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>Glucocerebrosidase (GCase), encoded by the <italic toggle="yes">GBA1</italic> gene, is a critical enzyme involved in the breakdown of glucocerebroside within lysosomes and is implicated in the formation of Lewy bodies in DLB and PD.<xref rid="acn352295-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="acn352295-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="acn352295-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> We have recently shown that GCase activity is associated with cognitive decline in PD and holds potential for predicting dementia at the early stages of the disease.<xref rid="acn352295-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="acn352295-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> However, reports on GCase activity and cognitive decline in DLB are scarce and few studies have studied the connection between GCase activity and cognitive decline across the LBD spectrum.</p><p>Contrary to <italic toggle="yes">GBA1/APOE&#x003b5;4</italic> gene carrier status, which remains unchanged over time, GCase activity and A&#x003b2;42 levels provide dynamic measures of the related pathways. Understanding the relationship between these biomarkers and cognitive decline is crucial, given the growing interest in disease&#x02010;modifying therapies targeting GCase activity and A&#x003b2; deposition,<xref rid="acn352295-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="acn352295-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> in addition to the need for more efficient biomarker&#x02010;driven clinical trial designs.</p><p>Against this background, we compared the association of cerebrospinal fluid (CSF) GCase activity and A&#x003b2;42 levels with longitudinal cognitive decline in two large DLB and PD cohorts from the European&#x02010;DLB (E&#x02010;DLB) Consortium and the Norwegian ParkWest Study.</p></sec><sec sec-type="methods" id="acn352295-sec-0006"><title>Methods</title><sec id="acn352295-sec-0007"><title>Participants</title><p>A total of 11 centers recruited patients with DLB (<italic toggle="yes">n</italic>&#x02009;=&#x02009;6) or PD (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5). Eligible cases were required to have undergone CSF sampling and have a minimum set of clinical and demographic information. Probable DLB<xref rid="acn352295-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;134) subjects were mostly referrals from outpatient clinics, including memory, movement disorder, geriatric medicine, psychiatric, and neurology clinics with cross&#x02010;center harmonization of diagnostic procedures from the E&#x02010;DLB consortium.<xref rid="acn352295-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Newly diagnosed PD<xref rid="acn352295-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> cases (<italic toggle="yes">n</italic>&#x02009;=&#x02009;120) were identified from the Norwegian ParkWest study, a prospective population&#x02010;based longitudinal cohort study of patients with incident PD.<xref rid="acn352295-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The local ethics committees approved each study and all participants signed written informed consent. We harmonized demographic and medical history data both at baseline and during the follow&#x02010;up period. To assess global cognition, we utilized the Mini&#x02010;Mental State Examination (MMSE).<xref rid="acn352295-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Motor severity was evaluated using the Unified PD Rating Scale (UPDRS) part III or the Movement Disorder Society&#x02010;UPDRS (MDS&#x02010;UPDRS) part III.<xref rid="acn352295-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> For a subset of patients we used the simplified conversion method to transform UPDRS scores to MDS&#x02010;UPDRS part III.<xref rid="acn352295-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Additional information on the cohorts can be found in Table&#x000a0;<xref rid="acn352295-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="acn352295-sec-0008"><title>
<styled-content style="fixed-case" toggle="no">CSF</styled-content> biomarkers</title><p>A detailed overview of CSF sample collection, handling, and storage, and reference CSF A&#x003b2;42 cutoff values are available in Table&#x000a0;<xref rid="acn352295-supitem-0001" ref-type="supplementary-material">S1</xref>.</p><p>GCase activity was measured in both DLB and PD patients with the same validated fluorometric in vitro assay.<xref rid="acn352295-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Detailed information on the methods used for GCase activity and CSF total protein content measurement in PD, including assay procedures, quality control measures, has been previously published,<xref rid="acn352295-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> this included the 117 patients with PD included in this work. Briefly, CSF samples were diluted 1:2 in assay buffer and supplemented with 4&#x02010;methylumbelliferyl&#x02010;&#x003b2;&#x02010;D&#x02010;glucopyranoside as a substrate. After incubation at 37&#x000b0;C for 3&#x02009;h, the reaction was stopped by adding 0.2&#x02009;M glycine pH&#x02009;10.2 and the concentration of the fluorescent cleavage product, 4&#x02010;methylumbelliferyl, was measured (Excitation: 360&#x02009;nm/Emission: 446&#x02009;nm). All samples were analyzed in triplicates. Single replicate values deviating more than twofold from the mean of the other two replicates were identified as outliers and excluded (<italic toggle="yes">n</italic>&#x02009;=&#x02009;12; 6.9%). Since PD and DLB samples were analyzed on three separate dates, each run included quality control samples on every plate to ensure reliability and consistency, demonstrating satisfactory interassay reproducibility. The lower limit of quantification for GCase activity in the DLB cohort assay was determined to be 0.190&#x02009;mU/mL, corresponding to a signal 10 standard deviations above background. Additionally, the lower limit of detection, defined as a signal 2 standard deviations above background, was found to be 0.053&#x02009;mU/mL. Mean GCase activity in the DLB CSF samples was 0.97&#x02009;mU/mL (range 0.1&#x02013;1.9). Mean sample CV% was 7.4 (range 0.3&#x02013;30.0). Only two samples exceeded a CV of 20%. Intraassay CV% was 4.7 (five plates, quality control samples on each plate). One unit of GCase activity was defined as amount of enzyme that hydrolyses 1&#x02009;nmol of substrate/min at 37&#x000b0;C. Total protein content was measured using a bicinchoninic acid assay (Thermo Fisher Scientific). Samples were run in duplicate at 1:2 dilution. The LLOQ was 0.14&#x02009;mg/mL. Mean protein content was 0.8&#x02009;mg/mL (range 0.5&#x02013;1.5). Mean sample CV% was 3.3 (range 0.04&#x02013;27.7). Only two samples exceeded a CV of 20%. Intraassay CV% was 9.5%. One sample was excluded due to technical reasons (protein concentration above the ULOQ of 4.2&#x02009;mg/mL). The final DLB cohort consisted of 121 patients.</p><p>There was a positive correlation between the total protein concentration and the GCase activity per mL of CSF in both groups (DLB: Kendall tau&#x02009;=&#x02009;0.112; <italic toggle="yes">P</italic>&#x02009;=&#x02009;0.01; PD group: Kendall tau <italic toggle="yes">b</italic>&#x02009;=&#x02009;0.268, <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001). To facilitate further analysis, the GCase enzymatic activity was adjusted by normalizing it to the CSF total protein content, resulting in specific activity reported as mU/mg.<xref rid="acn352295-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</p></sec><sec id="acn352295-sec-0009"><title>Genotyping</title><p>We obtained data on the four most commonly associated variants of <italic toggle="yes">GBA1</italic> mutations (E326K, T369M, N370S, L444P) with DLB and PD risk, along with information on the apolipoprotein E (<italic toggle="yes">APOE</italic>) &#x003b5;4 allele on a subset of participants (Table&#x000a0;<xref rid="acn352295-supitem-0001" ref-type="supplementary-material">S2</xref>). The procedures for genotyping PD patients have been described previously.<xref rid="acn352295-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> For DLB patients, information on <italic toggle="yes">GBA1</italic> and <italic toggle="yes">APOE</italic> status was available for one cohort from a previous whole exome sequencing effort.<xref rid="acn352295-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> For the remaining DLB cohorts, data on the genetic status was acquired using TaqMan genotyping assays (assay ID C___3084793_20/rs7412; C____904973_10/rs429358; C__57592026_10/rs2230288; C__64675913_10/rs75548401; Custom assay/ rs76763715; ThermoFisher) and the StepOnePlus Real&#x02010;Time PCR System (Applied Biosystems). Finally, to identify mutations in the L444P variant, we employed a polymerase chain reaction&#x02013;restriction fragment length polymorphism (PCR&#x02010;RFLP) technique. The PCR&#x02010;RFLP assay involved amplifying a fragment containing exons 8&#x02013;11 of the <italic toggle="yes">GBA1</italic> gene using the primers 5&#x02032;&#x02010;TGTGTGCAAGGTCCAGGATCAG&#x02010;3&#x02032; and 5&#x02032;&#x02010;ACCACCTAGAGGGGAAAGTG&#x02010;3&#x02032; with the MyTaq&#x02122; Mix polymerase from Meridian Bioscience. Subsequently, the PCR product was subjected to digestion using the <italic toggle="yes">Nci</italic>I restriction enzyme. For analysis, patients were grouped by genotype: <italic toggle="yes">APOE</italic>, carriers of the &#x003b5;4 allele versus non&#x02010;carriers; <italic toggle="yes">GBA1</italic>, carriers of one or more non&#x02010;synonymous <italic toggle="yes">GBA1</italic> mutations versus non&#x02010;carriers.</p></sec><sec id="acn352295-sec-0010"><title>Statistical analysis</title><p>Descriptive statistics were performed with means and standard deviations computed for continuous variables and frequencies and percentages for categorical variables. Group differences were compared using <italic toggle="yes">t</italic>&#x02010;tests and <italic toggle="yes">&#x003c7;</italic>
<sup>2</sup> tests, as appropriate. MMSE scores were transformed using the logarithm of (31&#x02010;MMSE), to reduce skewness.</p><p>CSF A&#x003b2;42 concentrations were divided into high or low, based on local reference standards (Table&#x000a0;<xref rid="acn352295-supitem-0001" ref-type="supplementary-material">S1</xref>). Due to differences in frozen storage time between the two diagnostic groups (median date for PD sample collection: October 2005, average frozen storage time: 15.4&#x02009;years; for DLB: median sample collection date: 30 November 2017, average frozen storage time: 3.5&#x02009;years), a known preanalytic factor influencing GCase robustness,<xref rid="acn352295-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> we conducted stratified analyses based on diagnoses. GCase activity was devided into tertiles. For the DLB group, the cutoffs were as follows: &#x0003e;1.46&#x02009;mU/mg (high activity), 1.46&#x02013;0.97&#x02009;mU/mg (intermediate activity), and &#x0003c;0.97&#x02009;mU/mg (low activity). For the PD group, the corresponding cut&#x02010;offs were 1.12&#x02009;mU/mg (high activity), 0.80&#x02013;1.12&#x02009;mU/mg (intermediate activity) and &#x0003c;0.80&#x02009;mU/mg (low activity).<xref rid="acn352295-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>To assess the association between biomarker levels and cognition, we ran linear mixed&#x02010;effects models for each biomarker with MMSE as the dependent variable using all available MMSE scores (the number of patients with DLB and PD diagnosis and their total or last recorded visit as well as total number of annual follow&#x02010;up assessments are available on the Fig.&#x000a0;<xref rid="acn352295-supitem-0001" ref-type="supplementary-material">S1</xref>). For modeling, the low GCase activity group and the high A&#x003b2;42 level group were set as the reference, respectively. These models incorporated an interaction term between time and each GCase/A&#x003b2;42 group as a fixed effect as well as a random intercept and slope for each participant to capture individual variations in baseline cognition and cognitive decline. A random intercept for each study center was also included. The models were then adjusted for potential confounding variables, including age, sex, years of education and gene mutation status for <italic toggle="yes">GBA1</italic> and <italic toggle="yes">APOE</italic>. In order to explore the relative importance of the different predictors, effect sizes were calculated as standardized coefficients to evaluate the change in the dependent variable in standard deviation units. Hypotheses were rejected in each model on an alpha level of 0.05 (two&#x02010;tailed). IBM SPSS Statistics 26 was used for data management, STATA 17 for data manipulation and modeling, and R version 4.0.5 for graphics.</p></sec></sec><sec sec-type="results" id="acn352295-sec-0011"><title>Results</title><sec id="acn352295-sec-0012"><title>Characteristics of the <styled-content style="fixed-case" toggle="no">DLB</styled-content> and <styled-content style="fixed-case" toggle="no">PD</styled-content> participants at baseline</title><p>Baseline characteristics are provided in Table&#x000a0;<xref rid="acn352295-tbl-0001" ref-type="table">1</xref>. The maximum follow&#x02010;up time was 11.7&#x02009;years (median 10.9, IQR 2.9) for the PD group and 8.1&#x02009;years (median 2.1, IQR 2.3) for the DLB cohort. Both groups exhibited comparable distributions in terms of sex, MDS&#x02010;UPDRS part III, CSF A&#x003b2;42 and <italic toggle="yes">GBA1/APOE&#x003b5;4</italic> status. As anticipated, DLB patients were older and displayed lower MMSE scores at baseline.</p><table-wrap position="float" id="acn352295-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Cohort overview at baseline.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">DLB</th><th align="left" valign="bottom" rowspan="1" colspan="1">PD</th><th align="left" valign="bottom" rowspan="1" colspan="1">Total</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Total, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">121 (51.0)</td><td align="left" valign="top" rowspan="1" colspan="1">117 (49.0)</td><td align="left" valign="top" rowspan="1" colspan="1">238 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">71.7&#x02009;&#x000b1;&#x02009;7.1</td><td align="left" valign="top" rowspan="1" colspan="1">66.7&#x02009;&#x000b1;&#x02009;9.5</td><td align="left" valign="top" rowspan="1" colspan="1">69.2&#x02009;&#x000b1;&#x02009;8.7</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (Male), <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">66 (54.6)</td><td align="left" valign="top" rowspan="1" colspan="1">76 (65.0)</td><td align="left" valign="top" rowspan="1" colspan="1">142 (59.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Year of education</td><td align="left" valign="top" rowspan="1" colspan="1">9.8&#x02009;&#x000b1;&#x02009;4.5</td><td align="left" valign="top" rowspan="1" colspan="1">11.1&#x02009;&#x000b1;&#x02009;3.1</td><td align="left" valign="top" rowspan="1" colspan="1">10.4&#x02009;&#x000b1;&#x02009;3.9</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MMSE</td><td align="left" valign="top" rowspan="1" colspan="1">22.7&#x02009;&#x000b1;&#x02009;4.8</td><td align="left" valign="top" rowspan="1" colspan="1">27.7&#x02009;&#x000b1;&#x02009;2.4</td><td align="left" valign="top" rowspan="1" colspan="1">25.2&#x02009;&#x000b1;&#x02009;4.6</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MDS&#x02010;UPDRS III</td><td align="left" valign="top" rowspan="1" colspan="1">29.9&#x02009;&#x000b1;&#x02009;19.4</td><td align="left" valign="top" rowspan="1" colspan="1">29.0&#x02009;&#x000b1;&#x02009;12.5</td><td align="left" valign="top" rowspan="1" colspan="1">29.2&#x02009;&#x000b1;&#x02009;14.2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<italic toggle="yes">GBA1, n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;carriers</td><td align="left" valign="top" rowspan="1" colspan="1">91 (95.8)</td><td align="left" valign="top" rowspan="1" colspan="1">103 (88.8)</td><td align="left" valign="top" rowspan="1" colspan="1">194 (91.9)</td><td align="char" char="." rowspan="2" valign="top" colspan="1">0.06</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Carriers</td><td align="left" valign="top" rowspan="1" colspan="1">4 (4.2)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (11.2)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (8.1)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">
<italic toggle="yes">APOE&#x003b5;4, n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;carriers</td><td align="left" valign="top" rowspan="1" colspan="1">46 (61.3)</td><td align="left" valign="top" rowspan="1" colspan="1">81 (69.2)</td><td align="left" valign="top" rowspan="1" colspan="1">127 (66.2)</td><td align="char" char="." rowspan="2" valign="top" colspan="1">0.26</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Carriers</td><td align="left" valign="top" rowspan="1" colspan="1">29 (38.7)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (30.8)</td><td align="left" valign="top" rowspan="1" colspan="1">65 (33.9)</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">CSF A&#x003b2;42, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High</td><td align="left" valign="top" rowspan="1" colspan="1">53 (45.7)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (42.5)</td><td align="left" valign="top" rowspan="1" colspan="1">98 (44.1)</td><td align="char" char="." rowspan="2" valign="top" colspan="1">0.63</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Low</td><td align="left" valign="top" rowspan="1" colspan="1">63 (54.3)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (57.6)</td><td align="left" valign="top" rowspan="1" colspan="1">124 (55.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GCase, mU/mg</td><td align="left" valign="top" rowspan="1" colspan="1">1.20 (0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CSF total protein, &#x003bc;g/mL</td><td align="left" valign="top" rowspan="1" colspan="1">83.0 (16.3)</td><td align="left" valign="top" rowspan="1" colspan="1">85.4 (19.6)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr></tbody></table><table-wrap-foot id="acn352295-ntgp-0001"><fn id="acn352295-note-0001"><p>Values are presented as mean&#x02009;&#x000b1;&#x02009;SD, unless stated.</p></fn><fn id="acn352295-note-0002"><p>CSF, cerebrospinal fluid; MMSE, Minimal&#x02010; Mental State Examinations.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acn352295-sec-0013"><title>Impact of <styled-content style="fixed-case" toggle="no">GCase</styled-content> activity on cognition in <styled-content style="fixed-case" toggle="no">DLB</styled-content> and <styled-content style="fixed-case" toggle="no">PD</styled-content>
</title><p>In our initial linear mixed&#x02010;effects model, we explored the influence of baseline GCase activity on global cognitive function in DLB and PD throughout the follow&#x02010;up period.</p><p>Cross&#x02010;sectional comparisons at baseline demonstrated no significant differences in MMSE scores between the three GCase activity groups in either diagnostic group. Similarly, longitudinal analyses revealed no differences in rate of cognitive decline during follow&#x02010;up between DLB patients with low, intermediate or high GCase activity. In contrast and as previously shown by our group,<xref rid="acn352295-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> individuals with PD with low GCase activity experienced more rapid cognitive decline, with a decline rate of &#x02212;0.34&#x02009;MMSE points per year (95% CI &#x02212;0.62; &#x02212;0.17, <italic toggle="yes">P</italic>&#x02009;=&#x02009;0.02) compared to those with high GCase activity who experienced a decline of &#x02212;0.04&#x02009;MMSE points per year (95% CI &#x02212;0.14; 0.02).<xref rid="acn352295-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Importantly, our findings reveal that the observed rates of cognitive decline remained unaffected by the presence of <italic toggle="yes">GBA1</italic> and <italic toggle="yes">APOE&#x003b5;4</italic> carrier status (Table&#x000a0;<xref rid="acn352295-tbl-0002" ref-type="table">2</xref>, Fig.&#x000a0;<xref rid="acn352295-fig-0001" ref-type="fig">1</xref>). Moreover, the effect size for low GCase activity on cognition in the PD group was found to be 0.23, while for the DLB group, the effect size was 0.01.</p><table-wrap position="float" id="acn352295-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Association of GCase activity with annual changes in Mini&#x02010;Mental State Examination (MMSE) as determined by linear mixed models.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">MMSE</th><th align="left" colspan="3" valign="bottom" rowspan="1">Unadjusted</th><th align="left" colspan="3" valign="bottom" rowspan="1">Adjusted</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Est.</th><th align="left" valign="bottom" rowspan="1" colspan="1">Std. Err.</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x02010;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Est.</th><th align="left" valign="bottom" rowspan="1" colspan="1">Std. Err.</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="7" valign="top" rowspan="1">
<italic toggle="yes">DLB</italic>
</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">GCase lower tertile (ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.99</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.17</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.59</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.84</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">GCase middle tertile (vs. ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.15</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.84</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.86</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">GCase higher tertile (vs. ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.22</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.16</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.22</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.66</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.05</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GBA1 status</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.37</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APOE&#x003b5;4 status</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.49</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (female vs. male)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Years of education</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">
<italic toggle="yes">PD</italic>
</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">GCase lower tertile (ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.94</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.39</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.47</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">GCase middle tertile (vs. ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.06</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.65</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.12</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.67</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">GCase higher tertile (vs. ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.43</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.07</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.07</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GBA1 status</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.12</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APOE&#x003b5;4 status</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (female vs. male)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Years of education</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr></tbody></table></table-wrap><fig position="float" fig-type="Figure" id="acn352295-fig-0001"><label>Figure 1</label><caption><p>Estimated impact of GCase activity on cognition in DLB and PD.</p></caption><graphic xlink:href="ACN3-12-915-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="acn352295-sec-0014"><title>Impact of A&#x003b2;42 status on cognition in <styled-content style="fixed-case" toggle="no">MMSE</styled-content> in <styled-content style="fixed-case" toggle="no">DLB</styled-content> and <styled-content style="fixed-case" toggle="no">PD</styled-content>
</title><p>We further examined the influence of CSF A&#x003b2;42 levels on global cognitive function in DLB and PD throughout the follow&#x02010;up period. At baseline, cross&#x02010;sectional analyses showed that DLB patients with low versus high A&#x003b2;42 CSF levels did not differ in their cognitive performance in the unadjusted (<italic toggle="yes">P</italic>&#x02009;=&#x02009;0.75) but in the adjusted model (<italic toggle="yes">P</italic>&#x02009;=&#x02009;0.03). In longitudinal analyses, DLB patients with low baseline A&#x003b2;42 CSF levels experienced a more rapid cognitive decline (&#x02212;1.26&#x02009;MMSE points per year, 95% CI &#x02212;1.98 to &#x02212;0.80, <italic toggle="yes">P</italic>&#x02009;=&#x02009;0.03) during follow&#x02010;up compared to DLB patients with high baseline A&#x003b2;42 CSF levels (&#x02212;0.51&#x02009;MMSE points per year, 95% CI &#x02212;1.03 to &#x02212;0.22). These results remained unaffected by the presence of <italic toggle="yes">GBA1</italic> gene mutations, <italic toggle="yes">APOE&#x003b5;4</italic> status, and demographic factors (Table&#x000a0;<xref rid="acn352295-tbl-0003" ref-type="table">3</xref>, Fig.&#x000a0;<xref rid="acn352295-fig-0002" ref-type="fig">2</xref>). A similar trend was observed in the PD group, where the predicted decline for patients with low baseline A&#x003b2;42 CSF levels was more than doubled compared to those with high A&#x003b2;42 CSF levels (&#x02212;0.22&#x02009;MMSE points per year vs. &#x02212;0.09&#x02009;MMSE points per year). However, this difference did not reach statistical significance (<italic toggle="yes">P</italic>&#x02009;=&#x02009;0.06). Moreover, the effect size for low CSF A&#x003b2;42 on cognition in the PD group was found to be 0.11, while for the DLB group, the effect size was 0.18.</p><table-wrap position="float" id="acn352295-tbl-0003" content-type="Table"><label>Table 3</label><caption><p>Association of A&#x003b2;42 status with annual changes in Mini&#x02010;Mental State Examination (MMSE) as determined by linear mixed models.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">MMSE</th><th align="left" colspan="3" valign="bottom" rowspan="1">Unadjusted</th><th align="left" colspan="3" valign="bottom" rowspan="1">Adjusted</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Est.</th><th align="left" valign="bottom" rowspan="1" colspan="1">Std. Err.</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x02010;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Est.</th><th align="left" valign="bottom" rowspan="1" colspan="1">Std. Err.</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="7" valign="top" rowspan="1">
<italic toggle="yes">DLB</italic>
</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">A&#x003b2;42 high (ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.98</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.92</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.77</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.06</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.05</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">A&#x003b2;42 low (vs ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.75</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.29</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.05</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.07</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APOE&#x003b5;4 status</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.55</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GBA1 status</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.06</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.32</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (female vs male)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.22</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Years of education</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">
<italic toggle="yes">PD</italic>
</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">A&#x003b2;42 high (ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.96</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.50</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.06</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">A&#x003b2;42 low (vs. ref)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intercept</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.41</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Time</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APOE&#x003b5;4 status</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.00</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GBA1 status</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.22</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.17</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (female vs. male)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.22</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Years of education</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td></tr></tbody></table></table-wrap><fig position="float" fig-type="Figure" id="acn352295-fig-0002"><label>Figure 2</label><caption><p>Estimated impact of A&#x003b2;42 status on cognition in MMSE in DLB and PD.</p></caption><graphic xlink:href="ACN3-12-915-g002" position="anchor" id="jats-graphic-3"/></fig></sec></sec><sec sec-type="discussion" id="acn352295-sec-0015"><title>Discussion</title><p>In this longitudinal study, we investigated the relationship of CSF GCase activity and A&#x003b2;42 levels with cognitive decline across the LBD spectrum using two multicenter cohorts with DLB and PD. We found that CSF A&#x003b2;42 levels predicted cognitive decline in DLB, whereas GCase activity was more closely related to cognitive decline in PD. For both, the observed associations were independent of <italic toggle="yes">GBA1</italic> or <italic toggle="yes">APOE&#x003b5;4</italic> carrier status. These findings provide insight into the relative importance of the respective pathways in disease progression and have implications for trial design for these disease groups.</p><p>Both <italic toggle="yes">GBA1</italic> variants and further GCase dysfunction appear to predispose to accelerated &#x003b1;&#x02010;synuclein aggregation and Lewy body pathology.<xref rid="acn352295-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="acn352295-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> While many studies have shown an association between <italic toggle="yes">GBA1</italic> mutations and cognitive progression in PD and DLB,<xref rid="acn352295-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="acn352295-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> there has been limited research directly comparing the relationship of GCase activity and cognitive progression across the PD spectrum,<xref rid="acn352295-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="acn352295-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="acn352295-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="acn352295-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> and to the best of our knowledge, none in DLB. We have previously and here shown that shown that lower GCase activity is predictive of the annual rate of decline in MMSE score in PD.<xref rid="acn352295-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="acn352295-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> However, this was not the case in DLB. This is striking given that <italic toggle="yes">GBA1</italic> mutations are more prevalent in DLB compared to PD, and postmortem studies have shown that GCase activity is reduced in patients with DLB with and without <italic toggle="yes">GBA1</italic> muations.<xref rid="acn352295-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Although the reasons for this discrepancy are unclear, there are a number of potential explanations. While <italic toggle="yes">GBA1</italic> mutations are typically associated with reduced GCase activity,<xref rid="acn352295-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> impairments in GCase function can manifest through mechanisms beyond genetic mutations.<xref rid="acn352295-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> In newly diagnosed PD, characterized by alpha&#x02010;synuclein pathology as a central feature, GCase dysfunction may predominantly contribute to cognitive decline due to its direct involvement in alpha&#x02010;synuclein metabolism.<xref rid="acn352295-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="acn352295-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="acn352295-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> However, in DLB, cognitive impairment may arise from a complex interplay of multiple pathological processes,<xref rid="acn352295-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> and amyloid pathology may overshadow the predictive value of GCase activity and be more influential in driving cognitive decline in this disease. Additionally, factors such as neural reserve and cognitive abilities,<xref rid="acn352295-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> which are generally more preserved in newly diagnosed PD cases compared to DLB,<xref rid="acn352295-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> may influence the lack of association observed. Furthermore, the small effect size in our study suggests that larger cohort sizes or extended follow&#x02010;up periods may be necessary to observe significant associations. However, the E&#x02010;DLB cohort is characteristic of the participants available for clinical trials, and the median length of follow&#x02010;up aligns with typical trial settings. Thus, our findings imply that GCase activity may not be directly applicable to clinical trials mirroring our DLB population.</p><p>CSF A&#x003b2;42 on the other hand, is an established biomarker of cerebral A&#x003b2; deposition.<xref rid="acn352295-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> In advanced stages, nearly half of DLB patients exhibit abnormal levels indicative of A&#x003b2; co&#x02010;pathology.<xref rid="acn352295-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> In our study DLB cases with low CSF A&#x003b2;42 values experienced steeper decline in MMSE score than those with high A&#x003b2;42 profiles, independent of <italic toggle="yes">APOE&#x003b5;4</italic> status. These findings highlight a consistent association between low CSF A&#x003b2;42 levels and a more aggressive disease course in DLB.<xref rid="acn352295-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> By contrast, evidence regarding of A&#x003b2; brain deposition markers and cognitive decline in PD varies significantly based on a number of factors, including disease stage of PD and outcome measures.<xref rid="acn352295-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="acn352295-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="acn352295-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="acn352295-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> We observed that low A&#x003b2;42 CSF levels showed a trend toward faster MMSE decline in the PD group, although the statistical significance was marginal. In contrast, a previous study of our ParkWest cohort demonstrated an increased risk of dementia development within 5&#x02009;years among those with low CSF A&#x003b2;42 at diagnosis of PD.<xref rid="acn352295-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Combined, these findings are aligned with clinical&#x02010;pathological studies suggesting that A&#x003b2; brain deposition is most prominent in PD patients with earliest cognitive decline, while Lewy body pathology is thought to be responsible for cognitive decline in later stages of the disease.<xref rid="acn352295-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> This emphasizes the need for a more nuanced understanding of the disease for accurate predictions and targeted interventions.</p><sec id="acn352295-sec-0016"><title>Strenghts and limitations</title><p>Our study has strengths and limitations. Strengths include the international multicenter design to recruit patients, the relatively large sample size with available CSF, the standardized clinical assessments, and the longitudinal follow up. Our study also has limitations. First, we recognize the differences in recruitment and follow&#x02010;up between the population&#x02010;based PD cohort and the clinical&#x02010;based DLB cohorts in this study. Achieving population representativeness in DLB is challenging, and the limited length of follow&#x02010;up in this patient group is often due to the aggressive disease course and high mortality. Second, both DLB and PD are frequently misdiagnosed and we only have postmortem confirmation for a subgroup of patients (<italic toggle="yes">n</italic>&#x02009;=&#x02009;42)<xref rid="acn352295-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> from the ParkWest cohort. However, diagnoses for both groups were established by specialists over continued follow up and met widely acknowledged diagnostic criteria at final visit. Third, we assessed cognitive decline using the MMSE rather than detailed neuropsychological testing, which is more sensitive to detect subtle cognitive changes, particularly in executive or visuospatial functioning that are commonly affected in DLB and PD patients. Still, our findings hold significance as the MMSE is the most widely adopted cognitive screening tool and is included as the primary outcome measure in several ongoing clinical trials.<xref rid="acn352295-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Given the retrospective design of our study and the variability in biomarker collection across cohorts (specially for the DLB cohort), there were instances of missing data, particularly in genetic markers and other clinical considerations such as motor symptoms. This limitation is most evident in the analysis of the 4 <italic toggle="yes">GBA</italic> mutations variants, where incomplete data led to small sample sizes. As a result, we were unable to effectively explore the effects of <italic toggle="yes">GBA</italic> mutations categorized by severity. With respect to the biomarkers in this study, CSF A&#x003b2;42 levels in DLB patients were assessed locally at each center using different immunoassays, which could introduce variability. To account for this we harmonized the data using respective center&#x02010;specific reference values and the results were robust to possible variation introduced by the specific assay employed. Another consideration is the long storage time of the PD samples for the GCase assays, which introduced limitations in conducting direct comparisons between the two diagnostic groups. Finally, the method we chose for assessing GCase activity has some inherent limitations, such as not accounting for endogenous factors that could influence GCase activity, as well as the unknown correlation between CSF and tissue activity when measured simultaneously. However, a key strength is that our selection of the GCase measurement assay is one of the most widely adopted methods for assessing GCase activity in patients' biofluids, providing excellent sensitivity and performed consistently at a single site.</p></sec></sec><sec sec-type="conclusions" id="acn352295-sec-0017"><title>Conclusions</title><p>Our study provides important evidence on the relationship between brain A&#x003b2; deposition and GCase activity in the Lewy body disease spectrum and its association with cognitive decline. These findings offer valuable insights into the shared pathological pathways of both DLB and PD, enhancing our understanding of their expected progression independent of their genetic status. These results hold particular relevance for shaping future clinical trials focused on therapeutic interventions targeting these pathways. Additional studies, including the prodromal stages of these disorders, would be valuable for the field.</p></sec><sec id="acn352295-sec-0018"><title>Author Contributions</title><p>M.C.G.: Conception of work, methods, performed the analysis, writing&#x02014;reviewing, and editing. L.O: Methods, writing&#x02010; reviewing, and editing. J.L: Methods, writing&#x02014;reviewing, and editing. D.A.T&#x02010;R: Processed the data, performed the analysis, and designed the figures. O&#x02010;B.T, C.P, M.M, M.B, D.Al, K.R, E.P, J.H, C.F&#x02010;P: Contributed to clinical data collection and sample preparation, writing&#x02014;reviewing, and editing. D.A, G.A, J.M&#x02010;G: Methods, contributed to clinical data collection and sample preparation, writing&#x02014;reviewing, and editing. All authors discussed the results and contributed to the final manuscript.</p></sec><sec id="acn352295-sec-0020"><title>Funding Information</title><p>The PARKWEST study was supported by the Research Council of Norway (grant# 177966), the Western Norway Regional Health Authority (grant# 911218 and # 911949), and Reberg legacy and the Norwegian Parkinson's Research Foundation. The University of Stavanger supported MCG. The Czech Brain Aging Study (<ext-link xlink:href="http://www.cbas.cz" ext-link-type="uri">www.cbas.cz</ext-link>) was supported by project number LX22NPO5107 (MEYS): Financed by European Union&#x02014;Next Generation EU. Sant Pau: This work was supported by research grants from Institute of Health Carlos III (ISCIII), Spain PI18/00435, PI22/00611, INT19/00016, INT23/00048 to D.Al., and by the Department of Health Generalitat de Catalunya PERIS program SLT006/17/125 to D.Al.</p></sec><sec sec-type="COI-statement" id="acn352295-sec-0021"><title>Conflict of Interest</title><p>The authors declare no competing financial interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="acn352295-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="ACN3-12-915-s001.docx"/></supplementary-material></sec></body><back><ack id="acn352295-sec-0019"><title>Acknowledgements</title><p>The authors would like to express their deepest gratitude to the E&#x02010;DLB consortium and to the ParkWest Study as well as to the patients and staff at each study.</p></ack><sec sec-type="data-availability" id="acn352295-sec-0023"><title>Data Availability Statement</title><p>Qualified external researchers can request access to anonymized patient&#x02010;level data, respecting patient informed consent, from the corresponding author on reasonable request.</p></sec><ref-list content-type="cited-references" id="acn352295-bibl-0001"><title>References</title><ref id="acn352295-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="acn352295-cit-0001">
<string-name>
<surname>Aarsland</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ballard</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Halliday</surname>
<given-names>G</given-names>
</string-name>. <article-title>Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?</article-title>
<source>J Geriatr Psychiatry Neurol</source>. <year>2004</year>;<volume>17</volume>(<issue>3</issue>):<fpage>137</fpage>&#x02010;<lpage>145</lpage>.<pub-id pub-id-type="pmid">15312277</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="acn352295-cit-0002">
<string-name>
<surname>Gonzalez</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Tovar&#x02010;Rios</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Alves</surname>
<given-names>G</given-names>
</string-name>, et&#x000a0;al. <article-title>Cognitive and motor decline in dementia with Lewy bodies and Parkinson's disease dementia</article-title>. <source>Mov Disord Clin Pract</source>. <year>2023</year>;<volume>10</volume>(<issue>6</issue>):<fpage>980</fpage>&#x02010;<lpage>986</lpage>.<pub-id pub-id-type="pmid">37332651</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="acn352295-cit-0003">
<string-name>
<surname>Szwedo</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Dalen</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>KF</given-names>
</string-name>, et&#x000a0;al. <article-title>GBA and APOE impact cognitive decline in Parkinson's disease: A 10&#x02010;year population&#x02010;based study</article-title>. <source>Mov Disord</source>. <year>2022</year>;<volume>37</volume>(<issue>5</issue>):<fpage>1016</fpage>&#x02010;<lpage>1027</lpage>.<pub-id pub-id-type="pmid">35106798</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="acn352295-cit-0004">
<string-name>
<surname>Bousiges</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Cretin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: evaluation of the Strasbourg cohort</article-title>. <source>Geroscience</source>. <year>2023</year>;<volume>46</volume>:<fpage>1527</fpage>&#x02010;<lpage>1542</lpage>.<pub-id pub-id-type="pmid">37653269</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="acn352295-cit-0005">
<string-name>
<surname>Wildsmith</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Holley</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Savage</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Skerrett</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Landreth</surname>
<given-names>GE</given-names>
</string-name>. <article-title>Evidence for impaired amyloid &#x003b2; clearance in Alzheimer's disease</article-title>. <source>Alzheimers Res Ther</source>. <year>2013</year>;<volume>5</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">23849219</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="acn352295-cit-0006">
<string-name>
<surname>Gonzalez</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Ashton</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Gomes</surname>
<given-names>BF</given-names>
</string-name>, et&#x000a0;al. <article-title>Association of Plasma p&#x02010;tau181 and p&#x02010;tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>1</issue>):<fpage>32</fpage>&#x02010;<lpage>37</lpage>.<pub-id pub-id-type="pmid">34807233</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="acn352295-cit-0007">
<string-name>
<surname>Foster</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Burack</surname>
<given-names>MA</given-names>
</string-name>, et&#x000a0;al. <article-title>Amyloid imaging of Lewy body&#x02010;associated disorders</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>15</issue>):<fpage>2516</fpage>&#x02010;<lpage>2523</lpage>.<pub-id pub-id-type="pmid">20922808</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="acn352295-cit-0008">
<string-name>
<surname>Hepp</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Vergoossen</surname>
<given-names>DLE</given-names>
</string-name>, <string-name>
<surname>Huisman</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Distribution and load of amyloid&#x02010;&#x003b2; pathology in Parkinson disease and dementia with Lewy bodies</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2016</year>;<volume>75</volume>(<issue>10</issue>):<fpage>936</fpage>&#x02010;<lpage>945</lpage>.<pub-id pub-id-type="pmid">27516115</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="acn352295-cit-0009">
<string-name>
<surname>Siderowf</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>SX</given-names>
</string-name>, <string-name>
<surname>Hurtig</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>CSF amyloid &#x003b2; 1&#x02010;42 predicts cognitive decline in Parkinson disease</article-title>. <source>Neurology</source>. <year>2010</year>;<volume>75</volume>(<issue>12</issue>):<fpage>1055</fpage>&#x02010;<lpage>1061</lpage>.<pub-id pub-id-type="pmid">20720189</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="acn352295-cit-0010">
<string-name>
<surname>Alves</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lange</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Blennow</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>CSF A&#x003b2;42 predicts early&#x02010;onset dementia in Parkinson disease</article-title>. <source>Neurology</source>. <year>2014</year>;<volume>82</volume>(<issue>20</issue>):<fpage>1784</fpage>&#x02010;<lpage>1790</lpage>.<pub-id pub-id-type="pmid">24748671</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="acn352295-cit-0011">
<string-name>
<surname>Melzer</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Stark</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Keenan</surname>
<given-names>RJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease</article-title>. <source>Front Neurol</source>. <year>2019</year>;<volume>10</volume>:<fpage>391</fpage>.<pub-id pub-id-type="pmid">31105633</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="acn352295-cit-0012">
<string-name>
<surname>Petrou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dwamena</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Foerster</surname>
<given-names>BR</given-names>
</string-name>, et&#x000a0;al. <article-title>Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review</article-title>. <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>7</issue>):<fpage>928</fpage>&#x02010;<lpage>935</lpage>.<pub-id pub-id-type="pmid">25879534</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="acn352295-cit-0013">
<string-name>
<surname>Murphy</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Gysbers</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Abbott</surname>
<given-names>SK</given-names>
</string-name>, et&#x000a0;al. <article-title>Reduced glucocerebrosidase is associated with increased &#x003b1;&#x02010;synuclein in sporadic Parkinson's disease</article-title>. <source>Brain</source>. <year>2014</year>;<volume>137</volume>(<issue>Pt 3</issue>):<fpage>834</fpage>&#x02010;<lpage>848</lpage>.<pub-id pub-id-type="pmid">24477431</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="acn352295-cit-0014">
<string-name>
<surname>Rocha</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Progressive decline of glucocerebrosidase in aging and Parkinson's disease</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2015</year>;<volume>2</volume>(<issue>4</issue>):<fpage>433</fpage>&#x02010;<lpage>438</lpage>.<pub-id pub-id-type="pmid">25909088</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="acn352295-cit-0015">
<string-name>
<surname>Chiasserini</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Paciotti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Eusebi</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies</article-title>. <source>Mol Neurodegener</source>. <year>2015</year>;<volume>27</volume>(<issue>10</issue>):<fpage>15</fpage>.</mixed-citation></ref><ref id="acn352295-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="acn352295-cit-0016">
<string-name>
<surname>Oftedal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Maple&#x02010;Gr&#x000f8;dem</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dalen</surname>
<given-names>I</given-names>
</string-name>, et&#x000a0;al. <article-title>Association of CSF glucocerebrosidase activity with the risk of incident dementia in patients with Parkinson disease</article-title>. <source>Neurology</source>. <year>2023</year>;<volume>100</volume>(<issue>4</issue>):<fpage>e388</fpage>&#x02010;<lpage>e395</lpage>.<pub-id pub-id-type="pmid">36253102</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="acn352295-cit-0017">
<string-name>
<surname>Oftedal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lange</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>KF</given-names>
</string-name>, et&#x000a0;al. <article-title>Early GCase activity is a predictor of long&#x02010;term cognitive decline in Parkinson's disease</article-title>. <source>Transl Neurodegener</source>. <year>2023</year>;<volume>12</volume>(<issue>1</issue>):<fpage>41</fpage>.<pub-id pub-id-type="pmid">37635244</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="acn352295-cit-0018">
<string-name>
<surname>Abdelnour</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>LL</given-names>
</string-name>, et&#x000a0;al. <article-title>Dementia with Lewy bodies drug therapies in clinical trials: systematic review up to 2022</article-title>. <source>Neurol Ther</source>. <year>2023</year>;<volume>12</volume>(<issue>3</issue>):<fpage>727</fpage>&#x02010;<lpage>749</lpage>.<pub-id pub-id-type="pmid">37017910</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="acn352295-cit-0019">
<string-name>
<surname>Cummings</surname>
<given-names>J</given-names>
</string-name>. <article-title>Anti&#x02010;amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics</article-title>. <source>Drugs</source>. <year>2023</year>;<volume>83</volume>:<fpage>569</fpage>&#x02010;<lpage>576</lpage>.<pub-id pub-id-type="pmid">37060386</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="acn352295-cit-0020">
<string-name>
<surname>McKeith</surname>
<given-names>IG</given-names>
</string-name>, <string-name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</string-name>, et&#x000a0;al. <article-title>Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium</article-title>. <source>Neurology</source>. <year>2017</year>;<volume>89</volume>(<issue>1</issue>):<fpage>88</fpage>&#x02010;<lpage>100</lpage>.<pub-id pub-id-type="pmid">28592453</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="acn352295-cit-0021">
<string-name>
<surname>Oppedal</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Borda</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Westman</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Aarsland</surname>
<given-names>D</given-names>
</string-name>. <article-title>European DLB consortium: diagnostic and prognostic biomarkers in dementia with Lewy bodies, a multicenter international initiative</article-title>. <source>Neurodegener Dis Manag</source>. <year>2019</year>;<volume>9</volume>(<issue>5</issue>):<fpage>247</fpage>&#x02010;<lpage>250</lpage>.<pub-id pub-id-type="pmid">31580225</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="acn352295-cit-0022">
<string-name>
<surname>Hughes</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Daniel</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Kilford</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico&#x02010;pathological study of 100 cases</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1992</year>;<volume>55</volume>(<issue>3</issue>):<fpage>181</fpage>&#x02010;<lpage>184</lpage>.<pub-id pub-id-type="pmid">1564476</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="acn352295-cit-0023">
<string-name>
<surname>Alves</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Herlofson</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2009</year>;<volume>80</volume>(<issue>8</issue>):<fpage>851</fpage>&#x02010;<lpage>857</lpage>.<pub-id pub-id-type="pmid">19246476</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="acn352295-cit-0024">
<string-name>
<surname>Folstein</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Folstein</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>McHugh</surname>
<given-names>PR</given-names>
</string-name>. <article-title>&#x0201c;mini&#x02010;mental state&#x0201d;. A practical method for grading the cognitive state of patients for the clinician</article-title>. <source>J Psychiatr Res</source>. <year>1975</year>;<volume>12</volume>(<issue>3</issue>):<fpage>189</fpage>&#x02010;<lpage>198</lpage>.<pub-id pub-id-type="pmid">1202204</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0025"><label>25</label><mixed-citation publication-type="book" id="acn352295-cit-0025">
<string-name>
<surname>Fahn</surname>
<given-names>SER</given-names>
</string-name>. <part-title>UPDRS program members Parkinson's disease rating scale</part-title>. In: <person-group person-group-type="editor">
<string-name>
<surname>Fahn</surname>
<given-names>S</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Marsden</surname>
<given-names>CD</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Goldstein</surname>
<given-names>M</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Calne</surname>
<given-names>DB</given-names>
</string-name>
</person-group>, eds. <source>Recent Developments in Parkinson's Disease</source>. Vol <volume>2</volume>. <publisher-name>Macmillanm Healthcare Information</publisher-name>; <year>1987</year>:<fpage>153</fpage>&#x02010;<lpage>163</lpage>.</mixed-citation></ref><ref id="acn352295-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="acn352295-cit-0026">
<string-name>
<surname>Hentz</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Mehta</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Shill</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Driver&#x02010;Dunckley</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Beach</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Adler</surname>
<given-names>CH</given-names>
</string-name>. <article-title>Simplified conversion method for unified Parkinson's disease rating scale motor examinations</article-title>. <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>14</issue>):<fpage>1967</fpage>&#x02010;<lpage>1970</lpage>.<pub-id pub-id-type="pmid">26779608</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="acn352295-cit-0027">
<string-name>
<surname>Oftedal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Maple&#x02010;Gr&#x000f8;dem</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>F&#x000f8;rland</surname>
<given-names>MGG</given-names>
</string-name>, <string-name>
<surname>Alves</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lange</surname>
<given-names>J</given-names>
</string-name>. <article-title>Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>22098</fpage>.<pub-id pub-id-type="pmid">33328543</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="acn352295-cit-0028">
<string-name>
<surname>Parnetti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Paciotti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Eusebi</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Cerebrospinal fluid &#x003b2;&#x02010;glucocerebrosidase activity is reduced in parkinson's disease patients</article-title>. <source>Mov Disord</source>. <year>2017</year>;<volume>32</volume>(<issue>10</issue>):<fpage>1423</fpage>&#x02010;<lpage>1431</lpage>.<pub-id pub-id-type="pmid">28843015</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="acn352295-cit-0029">
<string-name>
<surname>Moreno&#x02010;Grau</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>de Rojas</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hern&#x000e1;ndez</surname>
<given-names>I</given-names>
</string-name>, et&#x000a0;al. <article-title>Genome&#x02010;wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: the GR@ACE project</article-title>. <source>Alzheimers Dement</source>. <year>2019</year>;<volume>15</volume>(<issue>10</issue>):<fpage>1333</fpage>&#x02010;<lpage>1347</lpage>.<pub-id pub-id-type="pmid">31473137</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="acn352295-cit-0030">
<string-name>
<surname>Persichetti</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Chiasserini</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Parnetti</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>7</issue>):<elocation-id>e101453</elocation-id>.<pub-id pub-id-type="pmid">24983953</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="acn352295-cit-0031">
<string-name>
<surname>G&#x000fc;ndner</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Duran&#x02010;Pacheco</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zimmermann</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Path mediation analysis reveals GBA impacts Lewy body disease status by increasing &#x003b1;&#x02010;synuclein levels</article-title>. <source>Neurobiol Dis</source>. <year>2019</year>;<volume>121</volume>:<fpage>205</fpage>&#x02010;<lpage>213</lpage>.<pub-id pub-id-type="pmid">30236861</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="acn352295-cit-0032">
<string-name>
<surname>Gaubert</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hourregue</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mouton&#x02010;Liger</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Exploring the link between GBA1 mutations and dementia with Lewy bodies, a mini&#x02010;review</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2022</year>;<volume>141</volume>:<elocation-id>104856</elocation-id>.<pub-id pub-id-type="pmid">36084847</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="acn352295-cit-0033">
<string-name>
<surname>Smith</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Schapira</surname>
<given-names>AHV</given-names>
</string-name>. <article-title>GBA variants and Parkinson disease: mechanisms and treatments</article-title>. <source>Cells</source>. <year>2022</year>;<volume>11</volume>(<issue>8</issue>):<fpage>1261</fpage>.<pub-id pub-id-type="pmid">35455941</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="acn352295-cit-0034">
<string-name>
<surname>Alcalay</surname>
<given-names>RN</given-names>
</string-name>, <string-name>
<surname>Wolf</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chiang</surname>
<given-names>MSR</given-names>
</string-name>, et&#x000a0;al. <article-title>Longitudinal measurements of glucocerebrosidase activity in Parkinson's patients</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2020</year>;<volume>7</volume>(<issue>10</issue>):<fpage>1816</fpage>&#x02010;<lpage>1830</lpage>.<pub-id pub-id-type="pmid">32888397</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="acn352295-cit-0035">
<string-name>
<surname>Omer</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Giladi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gurevich</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Glucocerebrosidase activity is not associated with Parkinson's disease risk or severity</article-title>. <source>Mov Disord</source>. <year>2022</year>;<volume>37</volume>(<issue>1</issue>):<fpage>190</fpage>&#x02010;<lpage>195</lpage>.<pub-id pub-id-type="pmid">34550621</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="acn352295-cit-0036">
<string-name>
<surname>Gegg</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Heales</surname>
<given-names>SJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains</article-title>. <source>Ann Neurol</source>. <year>2012</year>;<volume>72</volume>(<issue>3</issue>):<fpage>455</fpage>&#x02010;<lpage>463</lpage>.<pub-id pub-id-type="pmid">23034917</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="acn352295-cit-0037">
<string-name>
<surname>Mazzulli</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>Y</given-names>
</string-name>, et&#x000a0;al. <article-title>Gaucher disease glucocerebrosidase and &#x003b1;&#x02010;synuclein form a bidirectional pathogenic loop in synucleinopathies</article-title>. <source>Cell</source>. <year>2011</year>;<volume>146</volume>(<issue>1</issue>):<fpage>37</fpage>&#x02010;<lpage>52</lpage>.<pub-id pub-id-type="pmid">21700325</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="acn352295-cit-0038">
<string-name>
<surname>Fernandes</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Hartfield</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Christian</surname>
<given-names>HC</given-names>
</string-name>, et&#x000a0;al. <article-title>ER stress and autophagic perturbations Lead to elevated extracellular &#x003b1;&#x02010;synuclein in GBA&#x02010;N370S Parkinson's iPSC&#x02010;derived dopamine neurons</article-title>. <source>Stem Cell Reports</source>. <year>2016</year>;<volume>6</volume>(<issue>3</issue>):<fpage>342</fpage>&#x02010;<lpage>356</lpage>.<pub-id pub-id-type="pmid">26905200</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="acn352295-cit-0039">
<string-name>
<surname>Wong</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Krainc</surname>
<given-names>D</given-names>
</string-name>. <article-title>Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease</article-title>. <source>Mov Disord</source>. <year>2016</year>;<volume>31</volume>(<issue>11</issue>):<fpage>1610</fpage>&#x02010;<lpage>1618</lpage>.<pub-id pub-id-type="pmid">27619775</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="acn352295-cit-0040">
<string-name>
<surname>Howlett</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Whitfield</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias</article-title>. <source>Brain Pathol</source>. <year>2015</year>;<volume>25</volume>(<issue>4</issue>):<fpage>401</fpage>&#x02010;<lpage>408</lpage>.<pub-id pub-id-type="pmid">25103200</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="acn352295-cit-0041">
<string-name>
<surname>Wilson</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Nag</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>PA</given-names>
</string-name>, et&#x000a0;al. <article-title>Neural reserve, neuronal density in the locus ceruleus, and cognitive decline</article-title>. <source>Neurology</source>. <year>2013</year>;<volume>80</volume>(<issue>13</issue>):<fpage>1202</fpage>&#x02010;<lpage>1208</lpage>.<pub-id pub-id-type="pmid">23486878</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="acn352295-cit-0042">
<string-name>
<surname>Walker</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Stefanis</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Attems</surname>
<given-names>J</given-names>
</string-name>. <article-title>Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies &#x02013; current issues and future directions</article-title>. <source>J Neurochem</source>. <year>2019</year>;<volume>150</volume>(<issue>5</issue>):<fpage>467</fpage>&#x02010;<lpage>474</lpage>.<pub-id pub-id-type="pmid">30892688</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="acn352295-cit-0043">
<string-name>
<surname>Blennow</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mattsson</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Sch&#x000f6;ll</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hansson</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Zetterberg</surname>
<given-names>H</given-names>
</string-name>. <article-title>Amyloid biomarkers in Alzheimer's disease</article-title>. <source>Trends Pharmacol Sci</source>. <year>2015</year>;<volume>36</volume>(<issue>5</issue>):<fpage>297</fpage>&#x02010;<lpage>309</lpage>.<pub-id pub-id-type="pmid">25840462</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="acn352295-cit-0044">
<string-name>
<surname>van de Beek</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ooms</surname>
<given-names>FAH</given-names>
</string-name>, <string-name>
<surname>Ebenau</surname>
<given-names>JL</given-names>
</string-name>, et&#x000a0;al. <article-title>Association of the ATN research framework with clinical profile, cognitive decline, and mortality in patients with dementia with Lewy bodies</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>98</volume>(<issue>12</issue>):<fpage>e1262</fpage>&#x02010;<lpage>e1272</lpage>.<pub-id pub-id-type="pmid">35074893</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="acn352295-cit-0045">
<string-name>
<surname>van Steenoven</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Aarsland</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Weintraub</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Cerebrospinal fluid Alzheimer's disease biomarkers across the Spectrum of Lewy body diseases: results from a large multicenter cohort</article-title>. <source>J Alzheimers Dis</source>. <year>2016</year>;<volume>54</volume>(<issue>1</issue>):<fpage>287</fpage>&#x02010;<lpage>295</lpage>.<pub-id pub-id-type="pmid">27567832</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="acn352295-cit-0046">
<string-name>
<surname>Mihaescu</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Valli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Uribe</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Beta amyloid deposition and cognitive decline in Parkinson's disease: a study of the PPMI cohort</article-title>. <source>Mol Brain</source>. <year>2022</year>;<volume>15</volume>(<issue>1</issue>):<fpage>79</fpage>.<pub-id pub-id-type="pmid">36100909</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="acn352295-cit-0047">
<string-name>
<surname>Smith</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Malek</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Grosset</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cullen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gentleman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Grosset</surname>
<given-names>DG</given-names>
</string-name>. <article-title>Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2019</year>;<volume>90</volume>(<issue>11</issue>):<fpage>1234</fpage>&#x02010;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">31444276</pub-id>
</mixed-citation></ref><ref id="acn352295-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="acn352295-cit-0048">
<string-name>
<surname>Gonzalez</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Dalen</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Maple&#x02010;Gr&#x000f8;dem</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tysnes</surname>
<given-names>OB</given-names>
</string-name>, <string-name>
<surname>Alves</surname>
<given-names>G</given-names>
</string-name>. <article-title>Parkinson's disease clinical milestones and mortality</article-title>. <source>NPJ Parkinsons Dis</source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>58</fpage>.<pub-id pub-id-type="pmid">35550520</pub-id>
</mixed-citation></ref></ref-list></back></article>